JP2017534262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534262A5 JP2017534262A5 JP2017515139A JP2017515139A JP2017534262A5 JP 2017534262 A5 JP2017534262 A5 JP 2017534262A5 JP 2017515139 A JP2017515139 A JP 2017515139A JP 2017515139 A JP2017515139 A JP 2017515139A JP 2017534262 A5 JP2017534262 A5 JP 2017534262A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- nucleotide sequence
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020017583A JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2021169396A JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053068P | 2014-09-19 | 2014-09-19 | |
| US62/053,068 | 2014-09-19 | ||
| PCT/US2015/051089 WO2016044811A1 (en) | 2014-09-19 | 2015-09-18 | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017583A Division JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534262A JP2017534262A (ja) | 2017-11-24 |
| JP2017534262A5 true JP2017534262A5 (cg-RX-API-DMAC7.html) | 2018-10-25 |
| JP6657195B2 JP6657195B2 (ja) | 2020-03-04 |
Family
ID=55533940
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515139A Active JP6657195B2 (ja) | 2014-09-19 | 2015-09-18 | Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2017515138A Active JP6711819B2 (ja) | 2014-09-19 | 2015-09-21 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2020017583A Active JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020093109A Active JP7216045B2 (ja) | 2014-09-19 | 2020-05-28 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2021169396A Active JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
| JP2022176776A Pending JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2023006410A Ceased JP2023052506A (ja) | 2014-09-19 | 2023-01-19 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515138A Active JP6711819B2 (ja) | 2014-09-19 | 2015-09-21 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2020017583A Active JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020093109A Active JP7216045B2 (ja) | 2014-09-19 | 2020-05-28 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2021169396A Active JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
| JP2022176776A Pending JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2023006410A Ceased JP2023052506A (ja) | 2014-09-19 | 2023-01-19 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9914909B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3587446A1 (cg-RX-API-DMAC7.html) |
| JP (7) | JP6657195B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102683584B1 (cg-RX-API-DMAC7.html) |
| CN (4) | CN107002084B (cg-RX-API-DMAC7.html) |
| AU (4) | AU2015317351B2 (cg-RX-API-DMAC7.html) |
| BR (3) | BR122024000360A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2961654A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3200591T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2738705T3 (cg-RX-API-DMAC7.html) |
| IL (6) | IL292650B2 (cg-RX-API-DMAC7.html) |
| MX (4) | MX387135B (cg-RX-API-DMAC7.html) |
| RU (2) | RU2749922C2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016044811A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015KN00329A (cg-RX-API-DMAC7.html) | 2012-08-09 | 2015-07-10 | Univ Leland Stanford Junior | |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| US10106592B2 (en) | 2013-09-24 | 2018-10-23 | Medicenna Therapeutics Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| HK1256130A1 (zh) | 2015-07-21 | 2019-09-13 | City Of Hope | 用於嵌合抗原受体和其他受体的表达的t细胞 |
| US10975148B2 (en) * | 2015-08-05 | 2021-04-13 | CellabMED Inc. | Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed |
| US20190183931A1 (en) * | 2016-04-01 | 2019-06-20 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| AU2017240150C1 (en) * | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| CA3026778A1 (en) | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CN118652336A (zh) * | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| NZ751571A (en) * | 2016-09-16 | 2025-10-31 | Baylor College Medicine | Platform for activation and expansion of virus-specific t-cells |
| GB2564823B8 (en) | 2016-10-07 | 2022-06-29 | Tcr2 Therapeutics Inc | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| WO2018106972A1 (en) * | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN108395481B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018181207A1 (ja) * | 2017-03-27 | 2018-10-04 | ノイルイミューン・バイオテック株式会社 | キメラ抗原受容体 |
| WO2018191748A1 (en) | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| AU2018256436B2 (en) | 2017-04-19 | 2024-12-05 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| JP7391831B2 (ja) * | 2017-08-11 | 2023-12-05 | シティ・オブ・ホープ | Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用 |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| WO2019094498A1 (en) * | 2017-11-07 | 2019-05-16 | City Of Hope | Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CN109971712B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| EP3743445A1 (en) * | 2018-01-26 | 2020-12-02 | City of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP2021512635A (ja) * | 2018-02-12 | 2021-05-20 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的とするキメラ抗原受容体 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019178085A1 (en) * | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| BR112020018670A2 (pt) | 2018-03-14 | 2021-01-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor |
| WO2019195586A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| WO2019195596A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| US20220089718A1 (en) * | 2018-05-21 | 2022-03-24 | Biosceptre (Uk) Limited | Chimeric antigen receptors with modified linker domains and uses thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| EP3802579A1 (en) * | 2018-06-01 | 2021-04-14 | The Board of Trustees of the Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| CN120988098A (zh) | 2018-06-29 | 2025-11-21 | 希望之城公司 | 用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体 |
| KR102897600B1 (ko) * | 2018-08-10 | 2025-12-09 | 주식회사 유틸렉스 | 암항원 특이적 세포독성 t세포 |
| JP2022512922A (ja) * | 2018-11-06 | 2022-02-07 | ワシントン・ユニバーシティ | キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法 |
| WO2020191336A1 (en) | 2019-03-21 | 2020-09-24 | Yamaguchi, Yukiko | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| US20220145252A1 (en) | 2019-03-29 | 2022-05-12 | City Of Hope | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| US20220249560A1 (en) * | 2019-05-24 | 2022-08-11 | City Of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| WO2021004400A1 (zh) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| PH12022550102A1 (en) * | 2019-07-24 | 2022-11-21 | Regeneron Pharma | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| EP3769816A1 (en) * | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
| US20230076643A1 (en) | 2019-12-30 | 2023-03-09 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| EP4097127A2 (en) * | 2020-01-31 | 2022-12-07 | City of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES |
| US20230374085A1 (en) * | 2020-03-11 | 2023-11-23 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| CA3175123A1 (en) * | 2020-03-12 | 2021-09-16 | City Of Hope | Targeted chimeric antigen receptor modified t cells for treatment of il13r.alpha.2 positive malignancies |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4158030A4 (en) * | 2020-05-27 | 2024-06-26 | The Medical College of Wisconsin, Inc. | Improved lentiviral vector transfer plasmid and methods of use |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| AU2021323525A1 (en) * | 2020-08-11 | 2023-04-20 | Ichilov Tech Ltd. | Veto CAR-T cells |
| CA3194747A1 (en) * | 2020-09-10 | 2022-03-17 | Mustang Bio, Inc. | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
| WO2022098797A1 (en) * | 2020-11-04 | 2022-05-12 | Fred Hutchinson Cancer Research Center | Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy |
| US20230364138A1 (en) | 2020-11-23 | 2023-11-16 | City Of Hope | Engineered t cells for expression of chimeric anitgen receptors |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4255922A1 (en) | 2020-12-03 | 2023-10-11 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| CA3212593A1 (en) * | 2021-03-18 | 2022-09-22 | David Weiner | Dna-encoded bispecific antibodies targeting il13r?2 and methods of use in cancer therapeutics |
| JP2024514308A (ja) | 2021-03-30 | 2024-04-01 | シティ・オブ・ホープ | ＣＡＲ Ｔ細胞療法及びＩＦＮγ |
| US20230190799A1 (en) * | 2021-07-21 | 2023-06-22 | City Of Hope | Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy |
| CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
| EP4176895A1 (en) * | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
| WO2023130462A1 (zh) * | 2022-01-10 | 2023-07-13 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| EP4588939A1 (en) | 2024-01-16 | 2025-07-23 | Universitat de Barcelona | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| KR100490099B1 (ko) * | 1995-02-24 | 2005-11-28 | 더 제너럴 하스피털 코포레이션 | 수용체키메라에의한세포면역성의방향전환 |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| MXPA01001041A (es) | 1998-07-30 | 2002-06-04 | El Gobierno De Los Estados Uni | La timosina beta4 promueve la curacion de heridas. |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001034645A2 (en) * | 1999-11-11 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Mutated il-13 molecules and their uses |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| EP1392818A4 (en) | 2001-04-30 | 2005-01-05 | Hope City | FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US11278594B2 (en) * | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1501226B1 (en) | 2003-07-24 | 2007-09-19 | Matsushita Electric Industrial Co., Ltd. | Method, encoder and communication device for encoding parallel concatenated data |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7754441B2 (en) * | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| DE102004043271A1 (de) * | 2004-09-07 | 2006-03-09 | Linde Ag | Verfahren zur Synthese von Zirkoniumcarboxylaten |
| DK1814580T3 (en) | 2004-11-24 | 2016-12-12 | Hutchinson Fred Cancer Res | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| NZ569105A (en) * | 2005-12-21 | 2011-07-29 | Sentoclone Internat Ab | A method for the expansion of tumor-reactive CD4 positive T-helper and CD positive T-lymphocytes |
| CA2634072A1 (en) * | 2005-12-21 | 2007-06-28 | Universite De Montreal | Markers for memory t cells and uses thereof |
| ES2595307T3 (es) | 2007-01-31 | 2016-12-29 | Yeda Research And Development Company Limited | Células T reguladoras redirigidas, modificadas genéticamente y su uso en la supresión de enfermedades autoinmunes e inflamatorias |
| EP2195341B1 (en) * | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| JP2012501180A (ja) * | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
| TW201130511A (en) * | 2009-12-22 | 2011-09-16 | Novartis Ag | Soluble proteins for use as therapeutics |
| GB2481983A (en) * | 2010-07-12 | 2012-01-18 | Hart Fenton & Co Ltd | A ship including a gas tank room |
| CA2809255A1 (en) * | 2010-08-18 | 2012-02-23 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Methods of identifying central memory t cells and obtaining antigen-specific t cell populations |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112013024395B1 (pt) * | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| EP3590965A1 (en) * | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| EP2532740A1 (en) * | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SMT202100005T1 (it) * | 2012-08-20 | 2021-05-07 | Hutchinson Fred Cancer Res | Metodo e composizioni per immunoterapia cellulare |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
-
2015
- 2015-09-18 CN CN201580061133.2A patent/CN107002084B/zh active Active
- 2015-09-18 WO PCT/US2015/051089 patent/WO2016044811A1/en not_active Ceased
- 2015-09-18 BR BR122024000360-0A patent/BR122024000360A2/pt not_active Application Discontinuation
- 2015-09-18 EP EP19175730.1A patent/EP3587446A1/en not_active Withdrawn
- 2015-09-18 JP JP2017515139A patent/JP6657195B2/ja active Active
- 2015-09-18 CN CN202110969587.7A patent/CN113789336B/zh active Active
- 2015-09-18 MX MX2017003596A patent/MX387135B/es unknown
- 2015-09-18 KR KR1020177010183A patent/KR102683584B1/ko active Active
- 2015-09-18 IL IL292650A patent/IL292650B2/en unknown
- 2015-09-18 IL IL308324A patent/IL308324A/en unknown
- 2015-09-18 CA CA2961654A patent/CA2961654A1/en active Pending
- 2015-09-18 ES ES15775539T patent/ES2738705T3/es active Active
- 2015-09-18 AU AU2015317351A patent/AU2015317351B2/en active Active
- 2015-09-18 EP EP15775539.8A patent/EP3194433B1/en active Active
- 2015-09-18 BR BR112017005631-3A patent/BR112017005631A2/pt not_active IP Right Cessation
- 2015-09-18 RU RU2017111298A patent/RU2749922C2/ru active
- 2015-09-21 CA CA2961676A patent/CA2961676A1/en active Pending
- 2015-09-21 RU RU2017111300A patent/RU2763523C2/ru active
- 2015-09-21 JP JP2017515138A patent/JP6711819B2/ja active Active
- 2015-09-21 EP EP15842405.1A patent/EP3200591B2/en active Active
- 2015-09-21 MX MX2017003557A patent/MX383042B/es unknown
- 2015-09-21 DK DK15842405.1T patent/DK3200591T3/da active
- 2015-09-21 CN CN201580062281.6A patent/CN107404881B/zh active Active
- 2015-09-21 IL IL251188A patent/IL251188B/en unknown
- 2015-09-21 EP EP21166086.5A patent/EP3916084A1/en active Pending
- 2015-09-21 BR BR112017005630-5A patent/BR112017005630B1/pt not_active IP Right Cessation
- 2015-09-21 KR KR1020177010184A patent/KR102610715B1/ko active Active
- 2015-09-21 WO PCT/US2015/051280 patent/WO2016044853A1/en not_active Ceased
- 2015-09-21 CN CN202110690954.XA patent/CN113637640A/zh active Pending
- 2015-09-21 ES ES15842405T patent/ES2876235T5/es active Active
- 2015-09-21 KR KR1020237041649A patent/KR20230169455A/ko not_active Ceased
-
2016
- 2016-05-27 US US15/167,869 patent/US9914909B2/en active Active
-
2017
- 2017-03-15 IL IL251196A patent/IL251196B/en active IP Right Grant
- 2017-03-16 MX MX2021006400A patent/MX2021006400A/es unknown
- 2017-03-17 MX MX2021012720A patent/MX2021012720A/es unknown
-
2018
- 2018-03-12 US US15/918,901 patent/US10676717B2/en active Active
-
2020
- 2020-02-05 JP JP2020017583A patent/JP6986190B2/ja active Active
- 2020-05-06 US US16/867,803 patent/US20200318069A1/en active Pending
- 2020-05-28 JP JP2020093109A patent/JP7216045B2/ja active Active
- 2020-06-03 AU AU2020203651A patent/AU2020203651A1/en not_active Abandoned
-
2021
- 2021-02-02 IL IL280576A patent/IL280576B/en unknown
- 2021-10-15 JP JP2021169396A patent/JP7171871B2/ja active Active
- 2021-11-30 AU AU2021277651A patent/AU2021277651A1/en not_active Abandoned
-
2022
- 2022-05-08 IL IL292828A patent/IL292828A/en unknown
- 2022-11-02 JP JP2022176776A patent/JP2023014100A/ja active Pending
-
2023
- 2023-01-19 JP JP2023006410A patent/JP2023052506A/ja not_active Ceased
-
2024
- 2024-02-28 AU AU2024201326A patent/AU2024201326A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534262A5 (cg-RX-API-DMAC7.html) | ||
| JP2015096070A5 (cg-RX-API-DMAC7.html) | ||
| JP2014012688A5 (cg-RX-API-DMAC7.html) | ||
| EP3821011A4 (en) | TRANSPOSOME-ACTIVATED DNA/RNA SEQUENCING (TED RNA-SEQ) | |
| JP2016525888A5 (cg-RX-API-DMAC7.html) | ||
| JP2010088434A5 (cg-RX-API-DMAC7.html) | ||
| JP2017048194A5 (cg-RX-API-DMAC7.html) | ||
| JP2011155981A5 (cg-RX-API-DMAC7.html) | ||
| CA3062698A1 (en) | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof | |
| WO2018004308A3 (ko) | 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법 | |
| MX395611B (es) | Receptores de celulas t. | |
| JP2016185981A5 (cg-RX-API-DMAC7.html) | ||
| JP2016104015A5 (cg-RX-API-DMAC7.html) | ||
| MX372992B (es) | Vector de virus adeno-asociado. | |
| JP2010227108A5 (cg-RX-API-DMAC7.html) | ||
| JP2014518898A5 (cg-RX-API-DMAC7.html) | ||
| WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
| MX2017016101A (es) | Polinucleotidos y polipetidos de adenovirus. | |
| CL2013001124A1 (es) | Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo. | |
| EA201792080A1 (ru) | Гуманизированные анти-c1s антитела и способы их применения | |
| EA201990884A1 (ru) | АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2017501211A5 (cg-RX-API-DMAC7.html) | ||
| JP2018531624A5 (cg-RX-API-DMAC7.html) | ||
| JP2015038108A5 (cg-RX-API-DMAC7.html) | ||
| JP2014028813A5 (cg-RX-API-DMAC7.html) |